Drugs / L. johnsonii N6.2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02349360 Comparator | Aug 2015 → Dec 2016 | — | University of Florida | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L. johnsonii N6.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02349360 ↗ |
| Known as | Lactobacillus johnsonii N6.2 | “Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults.” PMID 28659913 ↗ Jun 2017 |
| Modality | Other / unclassified | “The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria...” NCT02349360 ↗ |
| Route | Oral | “Participants will consume 1 capsule (probiotic or placebo) daily for 8 weeks” NCT02349360 ↗ |